



**How to
Use This
Document**

This document is intended to summarize updates to the Wellfleet Rx National Preferred Formulary since the last formulary print version from 7/1/2020. These updates include both positive changes to existing formulary statuses and updates for newly approved medications. For all other medications not listed below, refer to the October 2020 National Preferred Formulary for information on formulary status.

**Positive Changes
Effective 10/1/2020 for All Users**

Move to Preferred Status

Asthma/COPD	SPIRIVA (ADD QL) STIOLTO (ADD QL)	Trade Relations Strategy
Behavioral Health	METHYLPHENIDATE ER (ADD QL)	Trade Relations Strategy
Cardiovascular	NEXLIZET (MAINTAIN PA)	Trade Relations Strategy
Dermatology	FLUORURACIL 0.5% CREAM (ADD PA)	Low Net Cost Strategy
Diabetes	STEGLUJAN (REMOVE EXCLUSION, ADD ST, ADD QL)	
Endocrine	EDEX 40MG (UPDATE ST)	
Eye Disorders	AZOPT (UPDATE ST) TRAVOPROST (ADD QL, ADD ST) ZERVIAE	Trade Relations Strategy
Gastrointestinal Disorders	BUDESONIDE	Low Net Cost Strategy
Hematological Disorders	ESPEROCT ZIEXTENZO (MAINTAIN PA)	Trade Relations Strategy
Immune Globulin	XEMBIFY (MAINTAIN PA)	
Infectious Disease	SOLOSEC (MAINTAIN QL, MAINTAIN ST)	Trade Relations Strategy
Neurological Disease	RUZURGI (MAINTAIN PA) VUMERITY (MAINTAIN PA)	Trade Relations Strategy
Ophthalmology	TRAVOPROST	Low Net Cost Strategy

Remove Step Therapy

Asthma/COPD	TRELEGY ELLIPTA	Trade Relations Strategy
Cardiovascular	OLMESARTAN OLMESARTAN/HCTZ	Low Net Cost Strategy
Gastrointestinal Disorders	BUDESONIDE	Clinical & Safety Strategy

**Negative Changes
 Effective 10/1/2020 for New Users
 Effective 1/1/2021 for Existing Users**

Move to Non-Preferred Status

Eye Disorders	ALREX BEPREVE ILEVRO PROLENSA (MAINTAIN ST)	Trade Relations Strategy
Gastrointestinal Disorders	ZELNORM (ADD ST, ADD QL, ADD AGE)	Trade Relations Strategy
Immunization	FLEBOGAMMA 10% - ALIGN ALL STRENGTHS	
Miscellaneous	JYNARQUE (MAINTAIN PA) - ALLIGN ALL STRENGTHS QBREXZA (MAINTAIN PA) SAMSCA (MAINTAIN PA) - ALLIGN ALL STRENGTHS	Trade Relations Strategy

Add Prior Authorization

Immunization	BIVIGAM GAMASTAN	Clinical & Safety Strategy
Immunosuppression/Modulation	ACTIMMUNE	Clinical & Safety Strategy
Neurological Disease	TIGLUTIK	Clinical & Safety Strategy
Urinary Tract Disorders	ELMIRON	Clinical & Safety Strategy

Add Step Therapy (Preferred Product)

Eye Disorder	MOXIFLOXACIN 0.5% SLN VISCOUS (MOXIFLOXACIN 0.5% SLN) RHOPRESSA (UPDATE ST) ROCKLATAN (UPDATE ST) SIMBRINZA (UPDATE ST)	Low Net Cost Strategy
--------------	--	-----------------------

Add Quantity Limit

Diabetes	TEST STRIPS #200/30 DAYS	Low Net Cost Strategy
----------	--------------------------	-----------------------

Move to Excluded (Preferred Product)

Asthma/COPD	AIRDUO RESPICLICK (ADVAIR HFA, BREO ELLIPTA, DULERA, SYMBICORT) FLUTICASONE/SALMETEROL (BRAND OVER GENERIC ADVAIR HFA)	Trade Relations Strategy
Autonomic Nervous System	MESTINON (PYRIDOSTIGMINE BROMIDE)	Low Net Cost Strategy
Behavior Health	CAPLYTA (ARIPIRAZOLE, OLANZAPINE, RISPERIDONE)	Trade Relations Strategy



	<p>CONCERTA (METHYLPHENIDATE ER) QUAZEPAM (ESTAZOLAM, LORAZEPAM) RELEXXI (METHYLPHENIDATE ER)</p>	
Cardiovascular	<p>FIRAZYR (ICATIBANT) LETAIRIS (AMBRISENTAN) PRALUENT (REPATHA) RANEXA (RANOLAZINE ER) TEKTURNA (ALISKIREN HEMIFUMARATE)</p>	Low Net Cost Strategy
Contraception	<p>ESTROSTEP FE (NORETH A-ET ESTRA/FE FUMARATE) GENERESS FE (NORETH-ETHINYL ESTRADIOL/IRON) NUVARING (ETONOGESTREL/ETHINYL ESTRADIOL) QUARTETTE (L-NORGEST-ETH ESTR/ETHIN ESTRA) SAFYRAL (DROSPIR/ETH ESTRA/LEVOMEFOL CA)</p>	Low Net Cost Strategy
Dermatology	<p>CARAC (FLUOROURACIL 2% SOLUTION, DICLOFENAC 3% GEL, IMIQUIMOD 5% CREAM) SCALACORT (HYDROCORTISONE) ZOVIRAX 5% OINT (ACYCLOVIR OINTMENT)</p>	Low Net Cost Strategy Trade Relations Strategy
Diabetes	<p>JENTADUETO (JANUMET, JANUMET XR) JENTADUETO (JANUMET, JANUMET XR) QTERN (GLYXAMBI, STEGLUJAN) TRADJENTA (JANUVIA) WAVESENSE TEST STRIPS (ONE TOUCH, FREESTYLE, HEALTHPRO, TRUE METRIX)</p>	Trade Relations Strategy
Endocrine	<p>CRINONE 8% (ENDOMETRIN) KORLYM (KETOCONAZOLE, LYSODREN, SIGNIFOR) NORTHERA (DESMOPRESSIN ACETATE TABLETS, DESMOPRESSIN ACETATE NASAL) SENSIPAR (CINACALCET) TRELSTAR (ELIGARD, FIRMAGON)</p>	Trade Relations Strategy
Eye Disorder	<p>ALPHAGAN P (BETAXOLOL, BRIMONIDINE, LEVOBUNOLOL, TIMOLOL, AZOPT) COMBIGAN (BETAXOLOL, BRIMONIDINE, LEVOBUNOLOL, TIMOLOL, AZOPT) LASTACFT (AZELASTINE, CROMOLYN, EPINASTINE, KETOTIFEN, OLOPATADINE, ZERVIATE) MOXEZA (MOXIFLOXACIN SOLUTION) PAZEO (AZELASTINE, CROMOLYN, EPINASTINE, KETOTIFEN, OLOPATADINE, ZERVIATE)</p>	Low Net Cost Strategy
Gastrointestinal Disorders	<p>AMITIZA (LINZESS, TRULANCE) CARAFATE 1GM/10 ML SUSP (SUCRAFATE) LIALDA (MESALAMINE)</p>	Trade Relations Strategy

Wellfleet is the marketing name used to refer to the insurance and administrative operations of Wellfleet Insurance Company, Wellfleet New York Insurance Company, and Wellfleet Group, LLC. All insurance products are administered or managed by Wellfleet Group, LLC. Product availability is based upon business and/or regulatory approval and may differ among companies. ©2019 Wellfleet Group, LLC. All Rights Reserved.

	NEXIUM PACKETS (ESOMEPRAZOLE) UCERIS (BUDESONIDE)	
Gout	ULORIC (FEBUXOSTAT)	Low Net Cost Strategy
Hematological Disorders	JADENU (DEFERASIROX) OXBRYTA (HYDROXYUREA, ADAKVEO, DROXIA) TAVALISSE (DOPTELET, PROMACTA, NPLATE) UDENYCA (FULPHILA, ZIEXTENZO)	Trade Relations Strategy
Hormonal Deficiency	CRINONE 4% (MEDROXYPROGESTERONE, MEGESTROL, NORETHINDRONE, PROGESTERONE)	Trade Relations Strategy
Immune Globulin	CUTAQUIG (GAMMAGARD LIQUID, GAMUNEX-C, XEMBIFY) GAMMAKED (GAMMAGARD, GAMUNEX-C, XEMBIFY) HIZENTRA (GAMMAGARD, GAMUNEX-C, XEMBIFY) PRIVIGEN (GAMMAGARD, GAMUNEX-C, XEMBIFY)	Trade Relations Strategy
Infectious Disease	CIPROFLOXACIN HCL-FLUOCINOLONE (CIPRODEX) FIRVANQ (VANCOMYCIN) NOXAFIL TABLETS (POSACONAZOLE TABLETS) SUSTIVA 600MG (EFAVIRENZ) XIFAXAN 200MG (AZITHROMYCIN, CIPROFLOXACIN)	Low Net Cost Strategy
Inflammatory	OTREXUP (RASUVO) DUROLANE (EUFLEXXA, MONOVISC, ORTHOVISC) SILIQ (HUMIRA, ENBREL, RINVOQ, XELJANZ) TALTZ (HUMIRA, ENBREL, RINVOQ, XELJANZ)	Trade Relations Strategy
Neoplastic Disease	ALECENSIA ALUNBERG (XALKORI, ZYKADIA) AVASTIN (MVASI, ZIRABEV) CALQUENCE (IMBRUVICA, VENCLEXTA) HERCEPTIN (KANJINTI, TRAZIMERA) HERCEPTIN HYLECTA (KANJINTI, TRAZIMERA) INREBIC (JAKAFI) NINLARO (KYPROLIS, VELCADE) OGIVI (KANJINTI, TRAZIMERA) TARGRETIN CAPSULES (BEXAROTENE) TRUXIMA (RUXIENCE)	Trade Relations Strategy
Neurological Disease	COPAXONE (GLATIRAMER) FIRDAPSE (RUZURGI)	Low Net Cost Strategy
Migraine	VYEPTI (AIMOVIG, AJOVY, EMGALITY)	Trade Relations Strategy
Miscellaneous	ELELYSO (CEREZYME) MOVIPREP (PEG-ELECTROLYTE SOLUTION, CLENPIQ, SUPREP)	Trade Relations Strategy



**October 2020 Changes
National Preferred Formulary**

Urinary Tract	PROCYSBI (CYSTAGON) VESICARE (SOLIFENACIN)	Trade Relations Strategy
---------------	---	--------------------------

Please note: The bolded medications are brands with a generic available.

RATIONALE OF CHANGES
<p><u>Trade Relations Strategy</u> Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.</p>
<p><u>Low Net Cost Strategy</u> Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.</p>
<p><u>Clinical/Safety Strategy</u> Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).</p>
<p><u>Regulatory Update</u> Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.</p>